Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AGLE 102

Next Previous
Drug Profile

AGLE 102

Alternative Names: AGLE-102; AGLE-103; Extracellular vesicle therapy - Aegle Therapeutics; MSC EVs - Aegle Therapeutics

Latest Information Update: 18 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aegle Therapeutics
  • Class Exosome therapies; Gene therapies; Skin disorder therapies
  • Mechanism of Action Collagen type VII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Burns; Epidermolysis bullosa dystrophica
  • Preclinical Graft-versus-host disease

Most Recent Events

  • 19 Nov 2024 Aegle Therapeutics completes the Phase-I/II clinical trials in Burns in USA (Topical) (NCT05078385)
  • 14 Aug 2024 Phase-I/II clinical trials in Epidermolysis bullosa dystrophica (In adolescents, In adults, In children, In the elderly) in USA (Topical) prior to August 2024 (NCT04173650)
  • 08 Jan 2024 Aegle Therapeutics plans a phase I/IIa trial for Epidermolysis bullosa dystrophica in USA (Topical), in Q1 2024 (NCT04173650)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top